文献速递哮喘

肾上腺素与选择性β2受体激动剂治疗急性哮喘的系统评价与荟萃分析

Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis.
PubMed 文献 · Thorax · 2021-09-30

17项研究(1299例)的荟萃分析显示,治疗失败(住院、插管或死亡)的合并Peto OR为0.99(0.75-1.32),p=0.95,证据质量低。仅招募成人的研究显示肾上腺素治疗失败 odds 更低,但无法确定肾上腺素联合选择性β2受体激动剂是否改善结局。

要点

  • 低质量证据表明肾上腺素与选择性β2受体激动剂治疗急性哮喘疗效相似。
  • 成人研究中肾上腺素治疗失败 odds 更低,但需高质量双盲RCT验证。
  • 无法确定肾上腺素联合选择性β2受体激动剂是否改善结局。

核心结论

  • 低质量证据提示肾上腺素与选择性β2受体激动剂在急性哮喘中疗效相似。
  • 需高质量双盲RCT确定肌注肾上腺素联合吸入或雾化选择性β2受体激动剂是否改善结局。

研究设计与样本

  • 17项研究(1299例参与者)贡献数据进入荟萃分析,总体证据质量低,存在显著统计异质性(I2=56%)。

主要发现

  • 治疗失败的合并Peto OR为0.99(0.75-1.32),p=0.95。
  • 招募年龄组与治疗失败 odds 估计相关,仅招募成人的研究显示肾上腺素治疗失败 odds 更低。
  • 无法确定肾上腺素联合选择性β2受体激动剂是否改善结局。

关键数值与推荐

  • 主要结局为治疗失败,包括住院、需插管或死亡。
  • 国际哮喘指南不推荐急性哮喘使用肾上腺素,除非合并过敏反应或血管性水肿;许多院前指南推荐在急性重度或危及生命哮喘中肌注肾上腺素联合雾化选择性β2受体激动剂。

临床怎么用

  • 急性哮喘中肾上腺素与选择性β2受体激动剂疗效相似,但证据质量低。
  • 成人急性哮喘中肾上腺素可能降低治疗失败 odds,但需高质量RCT确认。
  • 是否在选择性β2受体激动剂基础上加用肌注肾上腺素仍不确定。

局限性

  • 总体证据质量低。
  • 存在显著统计异质性(I2=56%)。
  • 无法确定肾上腺素联合选择性β2受体激动剂是否改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: International asthma guidelines recommend against epinephrine (adrenaline) administration in acute asthma unless associated with anaphylaxis or angio-oedema. However, administration of intramuscular epinephrine in addition to nebulised selective β2-agonist is recommended for acute severe or life-threatening asthma in many prehospital guidelines. We conducted a systematic review to determine the efficacy of epinephrine in comparison to selective β2-agonist in acute asthma. METHODS: We included peer-reviewed publications of randomised controlled trials (RCTs) that enrolled children or adults in any healthcare setting and compared epinephrine by any route to selective β2-agonist by any route for an acute asthma exacerbation. The primary outcome was treatment failure, including hospitalisation, need for intubation or death. RESULTS: Thirty-eight of 1140 studies were included. Overall quality of evidence was low. Seventeen studies contributed data on 1299 participants to the meta-analysis. There was significant statistical heterogeneity, I2=56%. The pooled Peto's OR for treatment failure with epinephrine versus selective β2-agonist was 0.99 (0.75 to 1.32), p=0.95. There was strong evidence that recruitment age group was associated with different estimates of the odds of treatment failure; with studies recruiting adults-only having lower odds of treatment failure with epinephrine. It was not possible to determine whether epinephrine in addition to selective β2-agonist improved outcomes. CONCLUSION: The low-quality evidence available suggests that epinephrine and selective β2-agonists have similar efficacy in acute asthma. There is a need for high-quality double-blind RCTs to determine whether addition of intramuscular epinephrine to inhaled or nebulised selective β2-agonist improves outcome. PROSPERO REGISTRATION NUMBER: CRD42017079472.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Baggott C, Hardy JK, Sparks J, et al. Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis. Thorax. 2021. PMID: 34593615. doi:10.1136/thoraxjnl-2021-217124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。